Results 191 to 200 of about 61,050 (237)

Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population‐Based Longitudinal Cohort Study

open access: yesDiabetes/Metabolism Research and Reviews, Volume 41, Issue 5, July 2025.
ABSTRACT Aims Type 2 diabetes mellitus (T2DM) is recognized for increasing the risk of dementia; however, conclusive evidence supporting interventions to mitigate this risk remains elusive. This study endeavours to ascertain whether the glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) correlate with reduced incidence of dementia.
Hung‐Wen Cheng   +4 more
wiley   +1 more source

Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 7, Page 3714-3724, July 2025.
Abstract Aims To describe temporal changes in the characteristics of medication‐initiator cohorts in persons with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods Adults with CKD and T2D initiating sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were identified in ...
Yuichiro Yano   +9 more
wiley   +1 more source

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 7, Page 3736-3746, July 2025.
Abstract Aims This study compares the therapeutic efficacy, gastrointestinal (GI) adverse event (AE) rates and the relationship between the therapeutic efficacy and GI AEs in randomized, placebo‐controlled clinical trials (RCTs) of GLP‐1 RAs and the dual GLP‐1/GIP agonist tirzepatide. Materials and Methods A systematic PubMed search identified 38 phase
Yu Mi Kang   +3 more
wiley   +1 more source

Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users: A nationwide cohort study in Korea

open access: yesDiabetes, Obesity and Metabolism, Volume 27, Issue 7, Page 3869-3881, July 2025.
Abstract Aims There is limited evidence regarding whether obesity modifies the association between the use of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) and the risk of cardiovascular events. We assessed whether baseline body mass index (BMI) modifies the association between SGLT2i use and the risk of major adverse cardiovascular events (MACE)
Hwa Yeon Ko   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy